MASAC RECOMMENDATION ON FUNDING OF THE OFFICE OF CELLULAR AND GENE THERAPIES

The following recommendation was approved by the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation on June 7, 2003, and adopted by the NHF Board of Directors on October 19, 2003.

Whereas the Office of Cellular and Gene Therapies (OCGT) of the FDA is responsible for regulatory oversight of therapies which may cure bleeding disorders;

Whereas the OCGT, a part of the Center for Biologics Evaluation and Review (CBER), has undergone significant reorganization as projects and resources have been shifted to the Center for Drug Evaluation and Review (CDER);

Whereas sufficient expertise and human resources are essential to safely move emerging technologies to potentially cure bleeding disorders into human clinical testing;

Therefore, the Medical and Scientific Advisory Council (MASAC) of the National Hemophilia Foundation recommends that sufficient resources be allotted to OCGT to allow for

1. A collaborative relationship to accelerate the development of innovative clinical studies, and
2. Rapid review of translational research from academic institutions and industry.

This material is provided for your general information only. NHF does not give medical advice or engage in the practice of medicine. NHF under no circumstances recommends particular treatment for specific individuals and in all cases recommends that you consult your physician or local treatment center before pursuing any course of treatment.

Copyright 2003 National Hemophilia Foundation. To facilitate the dissemination of these medical recommendations, reproduction of any material in this publication in whole or in part will be permitted provided: 1) a specific reference to the MASAC recommendation number and title is included and 2) the reproduction is not intended for use in connection with the marketing, sale or promotion of any product or service. NHF reserves the right to make the final determination of compliance with this policy. For questions or to obtain a copy of the most recent recommendations, please contact the NHF Director of Communications at 1-800-42-HANDI or visit the NHF website at www.hemophilia.org.